ByHeart, a next-generation infant nutrition company, announced it has secured $95 million in additional financing to support the continued US commercial launch and development of its innovation pipeline. So far, ByHeart has raised $395 million from investors, including D1 Capital Partners, Bellco Capital, Polaris Partners, Two River, OCV Partners, AF Ventures, Red Sea Ventures, Gaingels, and more.
The company also revealed the completion of its complete end-to-end domestic manufacturing chain, with new manufacturing facilities in Portland, OR, and Allerton, IA. This enables the brand to expand production of its breakthrough formula to meet the needs of 15% of the addressable market.
ByHeart’s end-to-end manufacturing allows for full control, ensuring all aspects of production meet the company’s rigorous quality standards.
Utilizing the latest in breast milk science, ByHeart brings babies clinically proven benefits such as easier digestion, less spit up, softer poops, more efficient weight gain, and enhanced nutrient absorption, and empowers parents to feel confident about their feeding decisions. And ByHeart ran the largest clinical trial by a new infant formula brand in 25 years and was the first to add a comparison to breast milk.
The company is rapidly expanding and has recently launched in Thrive Market, a healthy and sustainable online grocer. And Thrive Market carefully selected ByHeart as a partner in its mission to provide families with the top healthy food brands and natural products.
By the end of the year, ByHeart will expand to several additional retailers, making its clean, science-backed recipe easily available to parents everywhere.
Along with Thrive Market, ByHeart is currently available direct-to-consumer at byheart.com and at Target nationwide in store and online. With a steadfast commitment to gold-standard nutrition, ByHeart proudly brings its formula to more babies across the nation.
KEY QUOTES:
“ByHeart’s foundation was built on a culture of innovation—incorporating clinical trials, highest quality ingredients, advanced nutrition science and a proprietary recipe—from day one. We are committed to doing better for babies and their parents, and that means continued investments into end-to-end manufacturing, scientific advancement and meaningful innovation in an industry that so desperately needed it.”
- Ron Belldegrun, CEO and Co-Founder of ByHeart
“Polaris is delighted to continue to support the expansion of ByHeart’s infant-first mission. In the long-stagnant infant formula space, ByHeart’s evidence-based approach drives innovation to benefit the health and wellness of babies and families. Our investors and team recognize the responsibility we have to provide the highest standard of nutrition, crafted with scientific precision and the utmost care.”
- Amy Schulman, ByHeart’s Chair of the Board and Managing Partner at Polaris Partners
